医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

USANA Announces Plans to Open Indonesia Market

2015年04月15日 PM10:29
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

As the direct selling industry continues to boom around the world, USANA Health Sciences, a global nutritional company, today announced that it will commence operations in Indonesia later this year. Headquartered in the Jarkarta Central Business District, USANA’s presence in Indonesia will mark USANA’s 20th market worldwide.

“As we continue to build USANA’s global brand, we’re thrilled to open our doors in Indonesia,” said USANA President, Kevin Guest. “International growth is important to the vision of USANA, and we look forward to offering our Associates the opportunity to build in this promising market.”

Direct Selling in Indonesia

  • Broke into the Direct Selling’s Billion Dollar Market in 2011, with $1 billion in total sales and 10 percent total sales growth over 2010 statistics
  • Estimated 8.3 million residents are direct sellers
  • Fourth most populous country in the world
  • Fifth fastest growing economy – middle class expected to double in next five years

USANA will launch with its flagship product, the Essentials™, along with several of its key optimizers. The state-of-the-art building in Jakarta will house employee offices, a will-call center, a distributor meeting area and several large meeting rooms.

For more information about USANA’s products and company, visit USANA.com.

About USANA

Founded in 1992, USANA Health Sciences (NYSE: USNA) is a U.S.-based nutritional company that manufactures high-quality supplements, personal care and energy products in its FDA-registered facility in Salt Lake City. Learn more about USANA by visiting our web site http://www.usana.com or the official USANA blog http://whatsupusana.com.

CONTACT

USANA Health Sciences, Inc.
Ashley Collins, 801-954-7629
Executive
Director of Public Relations and Social Media
media(at)us.usana(dot)com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman
  • 硕迪增强董事会实力,任命Daniel G. Welch为董事长
  • Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
  • BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
  • Mohammed bin Rashid为2022年扎耶德可持续发展奖的10名获奖者颁奖